Vaccinology: time to change the paradigm?
CS Benn, AB Fisker, A Rieckmann, S Sørup… - The lancet infectious …, 2020 - thelancet.com
The existing vaccine paradigm assumes that vaccines only protect against the target
infection, that effective vaccines reduce mortality corresponding to the target infection's …
infection, that effective vaccines reduce mortality corresponding to the target infection's …
[HTML][HTML] Developing the concept of beneficial non-specific effect of live vaccines with epidemiological studies
P Aaby, CS Benn - Clinical Microbiology and Infection, 2019 - Elsevier
Background Epidemiological and immunological studies are increasingly reporting non-
specific effects (NSEs) of vaccines; ie vaccines may affect the risk and severity of non …
specific effects (NSEs) of vaccines; ie vaccines may affect the risk and severity of non …
Non-specific effects of vaccines: plausible and potentially important, but implications uncertain
Non-specific effects (NSE) or heterologous effects of vaccines are proposed to explain
observations in some studies that certain vaccines have an impact beyond the direct …
observations in some studies that certain vaccines have an impact beyond the direct …
[HTML][HTML] Adjuvant Systems for vaccines: 13 years of post-licensure experience in diverse populations have progressed the way adjuvanted vaccine safety is …
B Laupèze, C Hervé, A Di Pasquale, FT Da Silva - Vaccine, 2019 - Elsevier
Adjuvant Systems (AS) are combinations of immune stimulants that enhance the immune
response to vaccine antigens. The first vaccine containing an AS (AS04) was licensed in …
response to vaccine antigens. The first vaccine containing an AS (AS04) was licensed in …
Safety profile of the RTS, S/AS01 malaria vaccine in infants and children: additional data from a phase III randomized controlled trial in sub-Saharan Africa
Y Guerra Mendoza, E Garric, A Leach… - Human vaccines & …, 2019 - Taylor & Francis
ABSTRACT A phase III, double-blind, randomized, controlled trial (NCT00866619) in sub-
Saharan Africa showed RTS, S/AS01 vaccine efficacy against malaria. We now present in …
Saharan Africa showed RTS, S/AS01 vaccine efficacy against malaria. We now present in …
[HTML][HTML] Choices in vaccine trial design in epidemics of emerging infections
Choices in vaccine trial design in epidemics of emerging infections | PLOS Medicine Skip to
main content Advertisement PLOS Medicine Browse Current Issue Journal Archive Special …
main content Advertisement PLOS Medicine Browse Current Issue Journal Archive Special …
[HTML][HTML] Rabies vaccination of 6-week-old puppies born to immunized mothers: a randomized controlled trial in a high-mortality population of owned, free-roaming …
To achieve global elimination of human rabies from dogs by 2030, evidence-based
strategies for effective dog vaccination are needed. Current guidelines recommend inclusion …
strategies for effective dog vaccination are needed. Current guidelines recommend inclusion …
[HTML][HTML] Rabies vaccine is associated with decreased all-cause mortality in dogs
Evidence suggests that rabies vaccine may have non-specific protective effects in animals
and children. We analyzed four years of data (2012–2015) from an observational study of …
and children. We analyzed four years of data (2012–2015) from an observational study of …
Distinct helper T cell type 1 and 2 responses associated with malaria protection and risk in RTS, S/AS01E vaccinees
G Moncunill, M Mpina, AJ Nhabomba… - Clinical Infectious …, 2017 - academic.oup.com
Abstract Background The RTS, S/AS01E malaria vaccine has moderate efficacy, lower in
infants than children. Current efforts to enhance RTS, S/AS01E efficacy would benefit from …
infants than children. Current efforts to enhance RTS, S/AS01E efficacy would benefit from …
WHO's rollout of malaria vaccine in Africa: can safety questions be answered after only 24 months?
WHO’s rollout of malaria vaccine in Africa: can safety questions be answered after only 24
months? Page 1 WHO’s rollout of malaria vaccine in Africa: can safety questions be …
months? Page 1 WHO’s rollout of malaria vaccine in Africa: can safety questions be …